These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87. Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. Coart E; Barrado LG; Duits FH; Scheltens P; van der Flier WM; Teunissen CE; van der Vies SM; Burzykowski T; J Alzheimers Dis; 2015; 46(4):889-99. PubMed ID: 25869788 [TBL] [Abstract][Full Text] [Related]
88. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Qu Y; Ma YH; Huang YY; Ou YN; Shen XN; Chen SD; Dong Q; Tan L; Yu JT Neurosci Biobehav Rev; 2021 Sep; 128():479-486. PubMed ID: 34245759 [TBL] [Abstract][Full Text] [Related]
89. Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Engelborghs S Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466 [TBL] [Abstract][Full Text] [Related]
90. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Tarawneh R; D'Angelo G; Macy E; Xiong C; Carter D; Cairns NJ; Fagan AM; Head D; Mintun MA; Ladenson JH; Lee JM; Morris JC; Holtzman DM Ann Neurol; 2011 Aug; 70(2):274-85. PubMed ID: 21823155 [TBL] [Abstract][Full Text] [Related]
91. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Andreasen N; Minthon L; Davidsson P; Vanmechelen E; Vanderstichele H; Winblad B; Blennow K Arch Neurol; 2001 Mar; 58(3):373-9. PubMed ID: 11255440 [TBL] [Abstract][Full Text] [Related]
92. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. Hertze J; Minthon L; Zetterberg H; Vanmechelen E; Blennow K; Hansson O J Alzheimers Dis; 2010; 21(4):1119-28. PubMed ID: 21504133 [TBL] [Abstract][Full Text] [Related]
93. Diagnostic Biomarkers of Alzheimer's Disease as Identified in Saliva using 1H NMR-Based Metabolomics. Yilmaz A; Geddes T; Han B; Bahado-Singh RO; Wilson GD; Imam K; Maddens M; Graham SF J Alzheimers Dis; 2017; 58(2):355-359. PubMed ID: 28453477 [TBL] [Abstract][Full Text] [Related]
94. Prognostic value of amyloid/tau/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer's disease. Delmotte K; Schaeverbeke J; Poesen K; Vandenberghe R Alzheimers Res Ther; 2021 Apr; 13(1):84. PubMed ID: 33879243 [TBL] [Abstract][Full Text] [Related]
95. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280 [TBL] [Abstract][Full Text] [Related]
96. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522 [TBL] [Abstract][Full Text] [Related]
97. An observation study of urinary biomarker exploratory in Alzheimer's disease using high-resolution mass spectrometry. Zhang Q; Wu S; Liu X; Yang J; Dong X; Zhou Y; Chen J; Li Y; Yang J Biomed Chromatogr; 2022 Sep; 36(9):e5421. PubMed ID: 35653409 [TBL] [Abstract][Full Text] [Related]